• Immuneering’s third-quarter 2026 net loss widened 62% year over year to $24.19 million.
• Research and development expenses jumped 91% to $20.72 million, primarily due to higher clinical costs and increased personnel.
• Cash, cash equivalents and marketable securities totaled $166.1 million at September 30, with operations funded into the fourth quarter of 2028.
• Phase 2 pancreatic cancer follow-up was extended because patients lived longer than projected; updated data are expected in first-half 2027.
• Ahead-of-schedule MAPKeeper 301 enrollment supports expansion to approximately 570 patients, potentially accelerating the currently expected mid-2028 topline readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291605PRIMZONEFULLFEED9856352) on October 29, 2026, and is solely responsible for the information contained therein.